IC 485

Drug Profile

IC 485

Latest Information Update: 06 Apr 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Array BioPharma; ICOS Corporation
  • Class Anti-inflammatories; Antirheumatics; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease; Rheumatoid arthritis

Most Recent Events

  • 23 Mar 2005 Discontinued - Phase-I for Rheumatoid arthritis in USA (PO)
  • 23 Mar 2005 Discontinued - Phase-II for Chronic obstructive pulmonary disease in USA (PO)
  • 12 Jul 2004 IC 485 is available for partnering (http://www.icos.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top